Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biology of IDH mutant cholangiocarcinoma.

Hepatology (Baltimore, Md.) - 1 May 2022

Wu Meng-Ju, Shi Lei, Merritt Joshua, Zhu Andrew X, Bardeesy Nabeel

Abstract excerpt

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes across human cancers. These hotspot gain-of-function mutations cause the IDH enzyme to aberrantly generate high levels of the oncometabolite, R-2-hydroxyglutarate, which competitively inhibits enzymes that regulate epigenetics, DNA repair, metabolism, and other processes. Among epithelial malignancies, IDH mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Bile Ducts, Intrahepatic
Share to Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Cholangiocarcinoma and Gallbladder Cancer Studies

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Pancreatic and Hepatic Oncology Research

Source

Identifiers

PMID: 35226770
DOI: 10.1002/hep.32424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biology of IDH mutant cholangiocarcinoma.PMID 35226770Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future PerspectivesSemantic proximity Read ↗

Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.Semantic proximity Read ↗

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future TherapiesSemantic proximity Read ↗

IDH mutations in liver cell plasticity and biliary cancer.Semantic proximity Read ↗

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.Semantic proximity Read ↗

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.Semantic proximity Read ↗

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read ↗

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.